Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.